Merge Healthcare announced that the company has started the year off with seven new contracts for its clinical trials solutions. These wins reflect continued momentum across all the clinical trials applications, and represent both new and expanded customer relationships.
In addition to the customizable myEDC platform, the Merge solution set for clinical trials includes applications for enterprise Electronic Data Capture (EDC), Interactive Voice and Web Response (IVR/IWR), electronic Patient Reported Outcomes (ePRO) via internet, phone or handheld device, and an endpoint adjudication module. The Merge CIMS platform for managing the imaging component of clinical trials was recently awarded Frost and Sullivan’s 2010 Healthcare Innovation for Medical Imaging Workflow Solutions of the Year. Merge capabilities extend across all stages of clinical trials, international studies, and many clinical specialty trials. The Merge suite of clinical trials solutions will be available for demonstration at the upcoming HIMSS conference February 20 – 24 in Orlando, Florida. Merge can be found at booth #3348.
“We’re thrilled with the recent momentum for this solution set,” said Jeff Surges, Merge CEO. “Clinical trials need efficient electronic workflow via an intuitive interface, and broad interoperability among associated applications, and imaging is a particular challenge. Just as with our iConnect platform for healthcare providers, Merge brings a new value proposition to these customers, and the recent wins show that the clinical trials market recognizes this.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.